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Background: A number of studies have reported on the effectiveness of sulbactam-based
therapies  for Acinetobacter baumannii infection; however, there is little evidence that
sulbactam-based  therapies are more or less effective than alternative therapies. Unfortu-
nately,  there is a distinct lack of high quality data (i.e., from randomized controlled trials)
available  on this issue. Therefore, we conducted a systematic review and meta-analysis com-
paring the efﬁcacy of sulbactam-based and non-sulbactam-based regimens in the treatment
of  A. baumannii infection.
Methods:  We  searched PubMed, MEDLINE, Biomedical Central, Google Scholar, the China
National  Knowledge Infrastructure, the Cochrane library, and the Directory of Open Access
using  the terms “sulbactam and baumannii” or “maxtam and baumannii”. Randomized con-
trolled  trials, controlled clinical studies, and cohort studies were considered for inclusion.
The  primary outcome was the clinical response rate for sulbactam-based therapy vs com-
parator  therapies.
Results:  Four studies (1 prospective, 3 retrospective) were included in the meta-
analysis.  Sulbactam was given in combination with ampicillin, carbapenem, or
cefoperazone  (n = 112 participants). Comparator drugs included colistin, cephalosporins,
anti-pseudomonas penicillins, ﬂuoroquinolones, minocycline/doxycycline, aminoglyco-
sides,  tigecycline, polymyxin, imipenem/cilastatin, and combination therapy (n = 107
participants).  The combined clinical response rate odds ratio did not signiﬁcantly favor
sulbactam-based  therapy over comparator therapy (odds ratio = 1.054, 95% conﬁdence inter-
val  = 0.550–2.019, p = 0.874), nor did any of the individual study odds ratios.
Conclusions: The available evidence suggests that sulbactam-based therapy may be similarlyefﬁcacious  to alternative antimicrobial therapies for the treatment of A. baumannii infection.
Further  research on this issue is warranted given the limited availability of data from high
quality/randomized  controlled trials.
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Introduction
Acinetobacter baumannii is a major cause of nosocomial infec-
tion,  particularly in critically ill patients,1,2 and has been
reported to be associated with signiﬁcant mortality in this
population.3 Common clinical manifestations of A. bauman-
nii  infection include pneumonia and bacteremia.2 Worryingly,
there  is evidence to suggest that the incidence of A. baumannii
infection may  be increasing.4,5 Hence, determining the most
effective  means of treatment is a pressing concern.
A. baumannii has developed resistance to many  conven-
tional  treatments and can therefore be very challenging to
treat.1,2,6 Indeed, researchers in the US have reported that
29.3%  of A. baumannii isolates examined from January 2004
to  September 2005 were multidrug resistant.7 Given this
evidence, it is perhaps not unsurprising that there is no avail-
able  consensus or guidelines outlining the optimal strategy
for  treating A. baumannii infection. Various antimicrobials
have been used to treat A. baumannii infection, including
carbapenems, polymyxins, tetracyclines and glycylcyclines,
aminoglycosides, ﬂuoroquinolones, and various combination
therapies.1,2 Of these antimicrobial agents, carbapenems have
traditionally  been used as the ﬁrst line treatment of choice;
however,  rates of resistance to this agent are often high,
rendering treatment ineffective.1,2 Polymyxins appear to be
effective  for treating A. baumannii infection, with low rates of
resistance,  although data from well-designed clinical trials are
lacking.1,2 Similarly, there is a paucity of clinical data regarding
effectiveness and resistance for the other antimicrobials thus
mentioned.
Sulbactam is a -lactamase inhibitor that is typically given
in  combination with ampicillin. Production of -lactamase
is  a common cause of bacterial resistance, rendering -
lactam  antibiotics such as penicillin ineffective.8 -Lactamase
inhibitors, including sulbactam, bind to -lactamase, thereby
increasing the susceptibility of the microorganism to co-
administered -lactam antibiotics.8 Indeed, most -lactamase
inhibitors do not exert antimicrobial activity if given alone.8
Sulbactam, however, has been demonstrated to have antimi-
crobial  properties, including against A. baumannii,9,10 which
are  thought to be mediated by binding to penicillin binding-
proteins.11
A large number of clinical studies have reported on the
effectiveness of sulbactam-based therapies for the treatment
of  A. baumannii infection.11,12 For instance, Kempf et al.
reported that sulbactam given in combination with colistin
may  offer a signiﬁcant beneﬁt over colistin monotherapy.13
Most recently, high dose sulbactam/ampicillin was  used
in  combination with rifampicin and fosfomycin to suc-
cessfully treat a case of postsurgical meningitis caused by
A.  baumannii.14 In another recent report, a patient with
drug-resistant A. baumannii-induced peritonitis was  success-
fully  treated with sulbactam/ampicillin in combination with
polymyxin  B. In vitro studies have also demonstrated the efﬁ-
cacy  of sulbactam in combination with various antibiotics
including minocycline and cefoperazone15 and fosfomycin.16Although the available evidence suggests that sulbactam-
based  therapies can be effective for the treatment of A.
baumannii infection, there is little evidence to suggest that 1 3;1  7(4):389–394
sulbactam-based therapies are more  or less effective than
alternative therapies. Indeed, there is a distinct lack of high
quality  data (i.e., from randomized controlled trials) available
on  this issue. In an attempt to overcome this limitation and
gain  a better understanding as to the effectiveness of sulbac-
tam  in the treatment of A. baumannii infection, we  conducted
a  systematic review of the available literature and performed
a  subsequent meta-analysis to compare the efﬁcacy, taken
as  the clinical response rate, of sulbactam-based and non-
sulbactam-based therapeutic regimens.
Materials  and  methods
Literature  search  strategy
The following biomedical databases were searched: PubMed;
MEDLINE  via Medscape; Biomedical Central; Google Scholar;
the  China National Knowledge Infrastructure; the Cochrane
library;  and the Directory of Open Access Journals. EMBASE
and  CINAHL were not searched due to lack of access. Gray lit-
erature  searched included the abstracts of Annual Meeting of
the  American Society of Infectious Disease, the American Col-
lege  of Chest Physicians, the American Lung Association, and
Clinicaltrials.gov. A loose search strategy using the key words
“sulbactam  and baumannii” or “maxtam and baumannii” was
employed  in order to maximize the possibility of identifying all
relevant  records. For PubMed and other databases, the follow-
ing  search limits were applied where possible: [Clinical Trial],
[Randomized Controlled Trial], [Clinical Conference], [Clini-
cal  Trial Phase I], [Clinical Trial Phase II], [Clinical Trial Phase
III],  [Clinical Trial Phase IV], [Consensus Development Confer-
ence],  [Controlled Clinical Trial], and [English]. The literature
was  searched from inception to December 2011.
Selection  criteria
Studies were eligible for inclusion in the meta-analysis if they
were  randomized controlled trials, controlled clinical studies,
or  cohort studies with designs comparing the clinical efﬁ-
cacy  of sulbactam-based therapy against other combinations
of  antimicrobial therapies for the treatment of A. baumannii
infection. In vitro studies and studies focusing on the suscep-
tibility  of clinical isolates/bacterial strains to antimicrobials
without clinical data were  excluded from the meta-analysis.
Data  extraction  and  quality  assessment
Two independent reviewers extracted the data from eligible
studies.  A third reviewer resolved any disagreements. The
following  information/data were extracted from studies that
met  the inclusion criteria: the name of the ﬁrst author, year
of  publication, type of study, number of participants in each
treatment  group, participants’ age and gender, name(s) of
drug(s)  given with sulbactam, name(s) of comparator drug(s),
and  the clinical response rate.
The primary outcome of interest was  the clinical response
rate  deﬁned as complete or partial resolution (improvement)
of  the symptoms/signs associated with A. baumannii infection
by  the end of therapy (72 h). Complete resolution was  deﬁned
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Databases searched
PubMed, Medline via Medscape, Biomedical Central,
Google Scholar, CNKI, Cochrane, and DOA.
Grey literature searched included: Annual meeting of
American Society of Infectious Disease, American
College of Chest Physicians, American Lung
Association, Clinicaltrials.gov
Records searched based on title and
abstract (n = 110)
Reasons for excluding records
Loboratory research/antibiotic-
resistance/bacteria susceptibility (n = 40)
Review articles (n =14)
Epidemiology/prevalence (n =9)
Case series (n =6)
Non-relevent to sulbactam efficacy (n = 27)
Non-english (n =1)
Duplicates (n =3)
Full-text articles reviewed (n =10)
Studies included in qualitative and
quantitative synthesis (n = 4)
Reason for excluding records
NOS score < 3 (n = 2)
No age or sex data (n = 1)
No control group (n = 1)
Sulbactam vs sulbactam/other antibiotics
(n = 1)
Single-arm interventional study (n = 1)
Fig. 1 – Flow diagram of study selection. CNKI, China National Knowledge Infrastructure; DOAJ, Directory of Open Access
Journals.
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nfection,  whereas partial resolution was  deﬁned as the reso-
ution  of some, but not all signs and symptoms of infection.
reatment failure is indicated by lack of obvious improvement
n  signs and symptoms of infection.
The Newcastle-Ottawa scale (NOS) score17 was  determined
o  assess the quality of each study included in the meta-
nalysis. Studies with a NOS score <3 were  classiﬁed as poor
uality  and were  excluded from this meta-analysis.
ata  analysis
he clinical response rate was  used to evaluate treatment
fﬁcacy. Odds ratios (ORs) with 95% conﬁdence intervals
ere  calculated for binary outcomes of patients treated with
ulbactam-based therapy and those who were treated with
omparator  drugs. A chi-square-based test for homogene-
ty  was  performed and the inconsistency index (I2) statistic
2as  determined. If I was  >50% or >75%, the studies were
onsidered to be heterogeneous or highly heterogeneous,
espectively. If I2 was  below 25%, the studies were  con-
idered to be homogeneous. If I2 statistic (>50%) indicatedheterogeneity between studies, a random-effects model was
calculated.  Otherwise, ﬁxed-effects models were  calculated.
Pooled  summary statistics of the ORs for the individual studies
are  shown. Pooled ORs were calculated and a 2-sided p-value
<0.05  was  considered to indicate statistical signiﬁcance. A
Funnel  plot and the fail-safe n (which indicates whether the
observed  signiﬁcance is spurious or not) were  used to assess
possible  publication bias. All analyses were  performed using
Comprehensive Meta-Analysis statistical software, version 2.0
(Biostat, Englewood, NJ, USA).
Results
Literature  search
A total of 110 studies were  identiﬁed by searching the speci-
ﬁed  databases (Fig. 1). Of these studies, 100 were  subsequently
excluded because they did not meet the eligibility criteria
based  on examination of the title and abstract. Full-text review
of  the remaining 10 studies led to the exclusion of an addi-
tional  six that did not meet the eligibility criteria. Therefore, a
total of four studies18–21 were included in the meta-analysis.
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Study name
Odds
ratio
Betrosian AP (2008)
Lee CM (2005)
Chan JD (2010)
Choi JY (2006)
Combined
1.500
1.103
0.464
1.125
1.054
0.313
0.451
0.070
0.244
0.550
7.186
2.698
3.086
5.177
2.019
0.507
0.215
-0.794
0.151
0.159
0.612
0.830
0.427
0.880
0.874
0.01
Favors
sulbactam
Favors
comparator
0.1 1 10 100
Lower
limit
Upper
limit Z value P value
Odds ratio and 95% CI
r drugs in the treatment of Acinetobacter baumannii infection.
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Fig. 3 – Funnel plot of the standard error by log odds ratioFig. 2 – Clinical response rate for sulbactam vs comparato
Study  characteristics
The characteristics of the four studies are summarized in
Table  1. These studies were  published between 2006 and 2010
and  included one prospective study20 and three retrospective
studies.18,19,21 There were  no randomized-controlled trials
included in the analyses. All studies achieved a NOS score of
3  or above. The studies included a total of 112 participants
treated with sulbactam and 107 participants treated with
other  comparator drugs. All patients had ventilator-associated
pneumonia in two of the studies20,21 and bacteremia in one
of  the studies.19 The type of infection was  not speciﬁed in
the  remaining study.18 Only two studies provided sulbactam
dosage information.20,21 Sulbactam was  given in combina-
tion  with ampicillin,20,21 carbapenem,18 or cefoperazone.19
Comparator drugs included colistin,20 cephalosporins,
anti-pseudomonas penicillins, or ﬂuoroquinolones with
aminoglycosides,18 minocycline/doxycycline, aminoglyco-
sides, tigecycline, polymyxin, or combination therapy,21 and
imipenem/cilastatin.19
Clinical  response  rate
None of the four studies included in the meta-analysis
had clinical response rate ORs that signiﬁcantly favored
sulbactam-based therapy over the comparator therapy or vice
versa (Fig. 2). There was  homogeneity in the response rate
among  the studies when the data were  pooled for analysis
(Q  = 0.931, I2 = 0.00%, p = 0.810); therefore a ﬁxed-effects model
of  analysis was  used. Further, the combined OR did not signif-
icantly  favor one form of therapy over the other. ORs ranged
from  0.464 to 1.500, with the overall OR being 1.054 (p = 0.874).
Publication  biasThe Funnel plot for publication bias (standard error by log OR
for  the clinical response rate) demonstrated no marked evi-
dence  of asymmetry (Fig. 3), indicating a lack of publication
bias.  For the clinical response rate, the combined effect size
yielded  a Z-value of 0.03966, with a corresponding p-value of
0.968.  As the overall clinical response rate was  not statistically
signiﬁcant, the fail-safe n value was  irrelevant.for  the clinical response rate. There was  no strong evidence
of  asymmetry and hence publication bias.
Discussion
To our knowledge, this is the ﬁrst systematic review and
subsequent meta-analysis to compare the efﬁcacy (clinical
response rate) of sulbactam-based vs non-sulbactam-based
therapies for the treatment of A. baumannii infection. Only a
small number of studies, involving a relatively small number
of  participants, met  the eligibility criteria and were  included
in  this meta-analysis.18–21 Analysis of the data extracted from
included  studies revealed that sulbactam-based therapy was
not  superior to alternative antimicrobial therapies for the
treatment  of A. baumannii or vice versa.
None of the individual clinical response rate ORs for the
studies  included in our analysis favored sulbactam-based
therapy over the comparator therapy. There was  considerable
between study variation in the type of comparator therapy
given  and, to a lesser extent, the drug given in combination
with sulbactam. Unsurprisingly, given the individual study
results,  the combined clinical response rate OR did not favor
one  treatment approach over the other. In terms of clinical
response, our ﬁndings therefore suggest that sulbactam-based
therapy is equally effective as non-sulbactam-based therapy
for  A. baumannii infection.
Our  meta-analysis has several limitations, most of which
relate  to those inherent in the available literature. Notably,
only  a small number of studies met  our inclusion criteria,
none  of which were randomized controlled trials. Hence, the
quality  of data extracted from these studies is not optimal. A
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Table 1 – Characteristics of studies included in the meta-analysis.
Study Study
type
Type of
infection
Sulbactam
dose
Drugs  given
with
sulbactam
Comparator drug(s) Participants
(sulbactam,
comparator)
Age  (sulbactam
vs  comparator)
%  Male
(sulbactam vs
comparator)
Response  rate
Betrosian
et al. (2008)
Randomized
prospective
cohort study
Ventilator-
associated
pneumonia
9  g/8 h (sulbac-
tam/ampicillin)
IV
Ampicillin Colistin 13, 15 72 ± 5 vs 67 ± 9 54 vs 47% 76.8 vs 73.3%
Lee et al.
(2005)
Retrospective
cohort study
Nosocomial
pan-drug
resistant A.
baumanniia
NS Carbapenem
(imipenem or
meropenem)
2nd/3rd  generation
cephalosporin,
anti-pseudomonas
penicillin, or
ﬂuoroquinolone (all
administered  with
aminoglycoside amikacin)
59,  30 71 ± 14 vs 71 ± 15 53 vs 57% 59 vs 60%
Chan et al.
(2010)
Retrospective
cohort study
Ventilator-
associated
pneumonia
1  g/6 h IV Ampicillin Minocycline/doxycycline,
aminoglycosides,
tigecycline and
polymyxin (or in
combination  therapy)
5, 50 40 (15–87) 72.7% 60 vs 79.1%
Choi et al.
(2006)
Retrospective
cohort study
Bacteremia NS Cefoperazone Imipenem/cilastatin 35, 12 45 ± 28 vs 55 ± 23 69 vs 67% 77.1 vs 75%
IV, intravenous; NS, not speciﬁed.
a No further details provided.
i s . 2 0
r
1
1
1
1
1
1
1
1
1
1
2394  b r a z j i n f e c t d 
further limitation is the relatively small number of partici-
pants  included in the studies and thus in our meta-analysis;
this obviously reduces the power of any statistical analy-
sis.  Other limitations include a lack of homogeneity in the
drugs  administered with sulbactam, the comparator drugs,
and  indeed the baseline characteristics of the participants.
The between study differences in the drugs administered
with sulbactam and the comparator drugs may  be particu-
larly  confounding given the inherent pharmacokinetic and
pharmacodynamic differences between some of these agents.
Additional  well-controlled studies are needed. Methodologi-
cal  limitations include the fact that the EMBASE and CINAHL
databases were  not included in the search and that non-
English  literature was  not considered.
In summary, the ﬁndings from our systematic review
and  meta-analysis suggest that sulbactam-based therapies
and  non-sulbactam-based therapies may  have similar efﬁ-
cacy  in the treatment of A. baumannii infection. We must
caution,  however, that the available evidence is limited in
many  respects (as previously outlined). Perhaps most impor-
tantly,  our review highlights the clear need for randomized,
well-controlled clinical trials to determine the most effective
means  of treating A. baumannii infection.
Funding
This work was  supported by grant no. 2010118 from the
Shanghai  Municipal Health Bureau.
Conﬂict  of  interest
The authors declare to have no conﬂict of interest.
 e  f  e  r  e  n  c  e  s
1. Garnacho-Montero J, Amaya-Villar R. Multiresistant
Acinetobacter baumannii infections: epidemiology and
management. Curr Opin Infect Dis. 2010;23:
332–9.
2. Karageorgopoulos DE, Falagas ME. Current control and
treatment of multidrug-resistant Acinetobacter baumannii
infections. Lancet Infect Dis. 2008;8:751–62.
3.  Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP,
Edmond  MB. Nosocomial bloodstream infections in US
hospitals: analysis of 24,179 cases from a prospective
nationwide surveillance study. Clin Infect Dis. 2004;39:
309–17.
4. Gaynes R, Edwards JR, National Nosocomial Infections
Surveillance System. Overview of nosocomial infections
caused by gram-negative bacilli. Clin Infect Dis.
2005;41:848–54.
5. Paul M, Weinberger M, Siegman-Igra Y, et al. Acinetobacter
baumannii: emergence and spread in Israeli hospitals
1997–2002. J Hosp Infect. 2005;60:256–60.
2 1 3;1  7(4):389–394
6. Vila J, Pachon J. Therapeutic options for Acinetobacter
baumannii infections: an update. Expert Opin Pharmacother.
2012;13:2319–36.
7. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility
among Acinetobacter calcoaceticus-baumannii complex and
Enterobacteriaceae collected as part of the Tigecycline
Evaluation and Surveillance. Trial J Infect. 2007;55:49–57.
8. Lode HM. Rational antibiotic therapy and the position of
ampicillin/sulbactam. Int J Antimicrob Agents. 2008;32:10–28.
9. Williams JD. Beta-lactamase inhibition and in vitro activity of
sulbactam  and sulbactam/cefoperazone. Clin Infect Dis.
1997;24:494–7.
0. Corbella X, Ariza J, Ardanuy C, et al. Efﬁcacy of sulbactam
alone and in combination with ampicillin in nosocomial
infections caused by multiresistant Acinetobacter baumannii. J
Antimicrob  Chemother. 1998;42:793–802.
1.  Rafailidis PI, Ioannidou EN, Falagas ME.  Ampicillin/sulbactam:
current status in severe bacterial infections. Drugs.
2007;67:1829–49.
2. Betrosian AP, Douzinas EE. Ampicillin–sulbactam: an update
on  the use of parenteral and oral forms in bacterial
infections. Expert Opin Drug Metab Toxicol. 2009;5:1099–112.
3. Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM.
Synergistic  activity of sulbactam combined with colistin
against colistin-resistant Acinetobacter baumannii. Int J
Antimicrob Agents. 2012;39:180–1.
4.  Mellon G, Clec’h C, Picard B, Cohen Y, Jaureguy F. Postsurgical
meningitis due to multiresistant Acinetobacter baumannii
successfully treated with high doses of ampicillin/sulbactam
combined with rifampicin and fosfomycin. J Infect
Chemother. 2012;18:958–60.
5. Pei G, Mao Y, Sun Y. In vitro activity of minocycline alone and
in  combination with cefoperazone–sulbactam against
carbapenem-resistant Acinetobacter baumannii. Microb Drug
Resist.  2012;18:574–7.
6. Santimaleeworagun W,  Wongpoowarak P, Chayakul P,
Pattharachayakul S, Tansakul P, Garey KW. In vitro activity of
colistin  or sulbactam in combination with fosfomycin or
imipenem  against clinical isolates of carbapenem-resistant
Acinetobacter baumannii producing OXA-23 carbapenemases.
Southeast Asian J Trop Med Public Health. 2011;42:890–900.
7. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa
Scale (NOS) for assessing the quality
of nonrandomised studies in meta-analyses; 2012. Available at:
http://www.ohri.ca/programs/clinical epidemiology/oxford.asp
[accessed 02.08.12].
8. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan-drug
resistant Acinetobacter baumannii. Scand J Infect Dis.
2005;37:195–9.
9. Choi JY, Kim CO, Park YS, et al. Comparison of efﬁcacy of
cefoperazone/sulbactam and imipenem/cilastatin for
treatment of Acinetobacter bacteremia. Yonsei Med J.
2006;47:63–9.
0. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE.
Efﬁcacy  and safety of high-dose ampicillin/sulbactam vs.
colistin  as monotherapy for the treatment of multidrug
resistant Acinetobacter baumannii ventilator-associated
pneumonia. J Infect. 2008;56:432–6.1.  Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and
clinical  outcomes of carbapenem-resistant Acinetobacter
baumannii ventilator-associated pneumonia. J Intensive Care
Med.  2010;25:343–8.
